V. Palya

TL;DR: In spite of the phylogenetic distance between the NDV F gene inserted into the vector vaccine and the challenge virus, the rHVT NDV vaccine provided good clinical protection and significantly reduced challenge virus shedding.

TL;DR: The results confirm the existence of a major antigenic drift among the Egyptian H5N1 strains such that, although protection against the "classical" 2007 HPAI H 5N1 Egyptian strain could be obtained with both types of vaccines, only vaccination with the rHVT-H5 vaccine protected against challenge with the "variant" 2008 HPAi H5n1 Egyptian strains.

TL;DR: Booster vaccination of rHVT-ND vaccinated birds with conventional ND vaccines significantly increased the level of anti-NDV serum antibodies and further reduced the oro-nasal excretion of challenge virus.

TL;DR: The data presented here highlight the advantages of this vaccine as a useful and reliable tool to complement biosecurity and sanitary policies for better controlling the disease due to HPAIV of H5 subtypes, when the vaccination is applied as a control measure.

TL;DR: This is the first reported efficacy study of an HVT-vectored ND vaccine against a velogenic NDV challenge in commercial turkeys and shows protection as early as 3 weeks of age based on lack of clinical signs, better body weight gain, and reduction of challenge virus shedding.